Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

APF530

Known as: APF-530 
A controlled-release formulation of a biodegradable poly(ortho ester) polymer, encapsulating the indazole derivative granisetron, with antiemetic… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Pharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial results.
e20518 Background: Up to 30% of patients continue to have chemotherapy-induced nausea and vomiting (CINV) despite use of… Expand
Is this relevant?
2016
2016
APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy.
AIM APF530, extended-release granisetron, provides sustained release for ≥5 days for acute- and delayed-phase chemotherapy… Expand
  • table 1
  • figure 2
  • table 2
  • figure 3
  • table 4
Is this relevant?
2016
2016
Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly…
BackgroundAPF530 provides controlled, sustained-release granisetron for preventing acute (0–24 h) and delayed (24–120 h… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2015
2015
Sustained antiemetic responses with APF530 (sustained-release granisetron) during multiple cycles of emetogenic chemotherapy.
BACKGROUND A phase 3 trial in patients with cancer who received chemotherapy has shown that subcutaneous (SC) APF530, a sustained… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
Is this relevant?
2015
2015
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
BACKGROUND APF530 is a novel sustained-release formulation of granisetron. In a Phase III trial, APF530 500 mg was noninferior to… Expand
Is this relevant?
2015
2015
Pharmacokinetics, safety, and efficacy of APF530 (extended-release granisetron) in patients receiving moderately or highly emetogenic chemotherapy: results of two Phase II trials
Background Despite advances with new therapies, a significant proportion of patients (>30%) suffer delayed-onset chemotherapy… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
2014
2014
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly…
PurposeSubcutaneous APF530 provides controlled sustained release of granisetron to prevent acute (0–24 h) and delayed (24–120 h… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
Is this relevant?
2014
2014
Biochronomer™ technology and the development of APF530, a sustained release formulation of granisetron
Granisetron and other 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists are first-line agents for preventing chemotherapy… Expand
  • figure 1
  • figure 3
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifloxacin on QTc prolongation
Background Regulatory concern about potential QT-interval prolongation by serotonin-receptor antagonist antiemetics prompted… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2009
2009
Phase III study of sustained release granisetron (APF530) compared to palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV).
9627 Background: APF530 is a polymeric formulation of granisetron providing sustained drug release over 5 days. Two doses (5 and… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE